Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital

Type of Contract: Supplies (incl. services) Description: This is a voluntary ex ante transparency (VEAT) notice. This notice acknowledges that CHI proposes to contract with Thermo Fisher Scientific Ireland Ltd for the supply, transfer, commissioning, maintenance and continued provision of support for primarily existing molecular equipment and the addition of …

CPV: 38000000 Laboratory, optical and precision equipments (excl. glasses), 85110000 Hospital and related services
Place of execution:
Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
Awarding body:
Children's Health Ireland at Crumlin
Award number:
1

1. Buyer

1.1 Buyer

Official name : Children's Health Ireland at Crumlin
Legal type of the buyer : Body governed by public law
Activity of the contracting authority : Health

2. Procedure

2.1 Procedure

Title : Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
Description : Type of Contract: Supplies (incl. services) Description: This is a voluntary ex ante transparency (VEAT) notice. This notice acknowledges that CHI proposes to contract with Thermo Fisher Scientific Ireland Ltd for the supply, transfer, commissioning, maintenance and continued provision of support for primarily existing molecular equipment and the addition of specialist equipment to enable the service to continue providing paediatric diagnostics nationally. The contract includes the provision existing and new equipment for Molecular Histopathology and Microbiology for the setup, processing and resulting of tests. The following sections highlight the reasons for the requirement of the specialist equipment. The Oncomine Childhood Cancer Research Assay (OCCRA) is a comprehensive, targeted NGS assay designed to assist researchers in the understanding of childhood and young adult cancer. OCCRA was designed and manufactured by Thermo Fisher Scientific for research use only. Molecular Histology includes the OCCRA DNA and RNA panels described above, which are part of comprehensive in-house validated test procedures, permitting one-assay approaches to ancillary diagnosis, prognostication and increasingly also need for theranostics on the paediatric solid tumour samples that come through CHI, the only paediatric oncology centre for children in Ireland. There is currently an agreement to proceed with an SLA for the Northern Irish paediatric cancer samples to be handled by the CHI laboratory. As the RNA fusion panel also covers all fusion transcripts identified in sarcomas, be they adult- or paediatric-type sarcomas, CHI have furthermore been in a position to critically support in the diagnosis and care of adult sarcoma patients whose biopsies have been referred from several of large teaching hospitals around in the country. CHI in-house validated Oncomine Childhood Cancer Research Assay (OCCRA) panels, while including all sarcoma-relevant molecular genetic findings, were developed to increase understanding of paediatric solid tumours and indeed do allow us to comprehensively interrogate for all relevant fusions, copy number changes, SNVs and indels relevant to paediatric solid tumours and propose optimal treatment of these patients from diagnosis and at relapse. As the Oncomine Childhood Cancer Research Assay (OCCRA) panel runs on the S5 platform only, other platforms are not taken into consideration at this point, as no other platforms have this comprehensive capability and it is not possible to piece together assays on other alternative platforms to achieve the same range of molecular genetic tests to cater to the requirements of CHI cancer patients. Additionally, the Irish Meningitis and Sepsis Reference Laboratory based at CHI at Temple St and the Molecular Microbiology Laboratory at CHI at Crumlin run a series of in-house developed INAB accredited tests for the diagnosis of a variety of infections. All of these tests were developed, validated, and run routinely on Thermo Fisher Scientific real-time PCR instruments. Changing from current Thermo Fisher Scientific technology to an alternative technology during the transfer and commissioning into the new children’s hospital would not be possible due to the onerous and extensive revalidation requirements of these tests, which include a high risk that the tests would not achieve acceptable results as compared to the test in use on Thermo Fisher platforms that will transfer and be upgraded into the new children’s hospital. In summary, there are no technically, clinically, financially or administratively reasonable or viable alternative or substitute solutions that could be implemented other than transferring the existing and if required, complement or replace with new Thermo Fisher platforms, that can meet the requirements of CHI for the aforementioned service and diagnostic testing.
Procedure identifier : 0b351b6d-3112-444d-aeab-d90c427dade3
Type of procedure : Negotiated without prior call for competition

2.1.1 Purpose

Main nature of the contract : Supplies
Additional nature of the contract : Services
Main classification ( cpv ): 38000000 Laboratory, optical and precision equipments (excl. glasses)
Additional classification ( cpv ): 85110000 Hospital and related services

2.1.4 General information

Legal basis :
Directive 2014/24/EU

5. Lot

5.1 Lot technical ID : LOT-0001

Title : Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
Description : Type of Contract: Supplies (incl. services) Description: This is a voluntary ex ante transparency (VEAT) notice. This notice acknowledges that CHI proposes to contract with Thermo Fisher Scientific Ireland Ltd for the supply, transfer, commissioning, maintenance and continued provision of support for primarily existing molecular equipment and the addition of specialist equipment to enable the service to continue providing paediatric diagnostics nationally. The contract includes the provision existing and new equipment for Molecular Histopathology and Microbiology for the setup, processing and resulting of tests. The following sections highlight the reasons for the requirement of the specialist equipment. The Oncomine Childhood Cancer Research Assay (OCCRA) is a comprehensive, targeted NGS assay designed to assist researchers in the understanding of childhood and young adult cancer. OCCRA was designed and manufactured by Thermo Fisher Scientific for research use only. Molecular Histology includes the OCCRA DNA and RNA panels described above, which are part of comprehensive in-house validated test procedures, permitting one-assay approaches to ancillary diagnosis, prognostication and increasingly also need for theranostics on the paediatric solid tumour samples that come through CHI, the only paediatric oncology centre for children in Ireland. There is currently an agreement to proceed with an SLA for the Northern Irish paediatric cancer samples to be handled by the CHI laboratory. As the RNA fusion panel also covers all fusion transcripts identified in sarcomas, be they adult- or paediatric-type sarcomas, CHI have furthermore been in a position to critically support in the diagnosis and care of adult sarcoma patients whose biopsies have been referred from several of large teaching hospitals around in the country. CHI in-house validated Oncomine Childhood Cancer Research Assay (OCCRA) panels, while including all sarcoma-relevant molecular genetic findings, were developed to increase understanding of paediatric solid tumours and indeed do allow us to comprehensively interrogate for all relevant fusions, copy number changes, SNVs and indels relevant to paediatric solid tumours and propose optimal treatment of these patients from diagnosis and at relapse. As the Oncomine Childhood Cancer Research Assay (OCCRA) panel runs on the S5 platform only, other platforms are not taken into consideration at this point, as no other platforms have this comprehensive capability and it is not possible to piece together assays on other alternative platforms to achieve the same range of molecular genetic tests to cater to the requirements of CHI cancer patients. Additionally, the Irish Meningitis and Sepsis Reference Laboratory based at CHI at Temple St and the Molecular Microbiology Laboratory at CHI at Crumlin run a series of in-house developed INAB accredited tests for the diagnosis of a variety of infections. All of these tests were developed, validated, and run routinely on Thermo Fisher Scientific real-time PCR instruments. Changing from current Thermo Fisher Scientific technology to an alternative technology during the transfer and commissioning into the new children’s hospital would not be possible due to the onerous and extensive revalidation requirements of these tests, which include a high risk that the tests would not achieve acceptable results as compared to the test in use on Thermo Fisher platforms that will transfer and be upgraded into the new children’s hospital. In summary, there are no technically, clinically, financially or administratively reasonable or viable alternative or substitute solutions that could be implemented other than transferring the existing and if required, complement or replace with new Thermo Fisher platforms, that can meet the requirements of CHI for the aforementioned service and diagnostic testing.
Internal identifier : 1

5.1.1 Purpose

Main nature of the contract : Supplies
Additional nature of the contract : Services
Main classification ( cpv ): 38000000 Laboratory, optical and precision equipments (excl. glasses)
Quantity : 1 hour

5.1.2 Place of performance

Country : Ireland
Anywhere
Additional information :

5.1.6 General information

Procurement Project not financed with EU Funds.
The procurement is covered by the Government Procurement Agreement (GPA) : yes

5.1.7 Strategic procurement

Aim of strategic procurement : No strategic procurement

5.1.16 Further information, mediation and review

Review organisation : The High Court of Ireland
TED eSender : European Dynamics S.A.

6. Results

6.1 Result lot ldentifier : LOT-0001

6.1.2 Information about winners

Winner :
Tender :
Tender identifier : Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
Identifier of lot or group of lots : LOT-0001
Contract information :
Identifier of the contract : Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
Title : Molecular Equipment, Transfer, Commissioning and Maintenance Services for the new children’s hospital
The contract is awarded within a framework agreement : no

8. Organisations

8.1 ORG-0001

Official name : Children's Health Ireland at Crumlin
Postal address : Crumlin
Town : Dublin
Country subdivision (NUTS) : Dublin ( IE061 )
Country : Ireland
Telephone : 01 4096598
Roles of this organisation :
Buyer

8.1 ORG-0002

Official name : The High Court of Ireland
Registration number : The High Court of Ireland
Department : The High Court of Ireland
Postal address : Four Courts, Inns Quay, Dublin 7
Town : Dublin
Postcode : D07 WDX8
Country subdivision (NUTS) : Dublin ( IE061 )
Country : Ireland
Telephone : +353 1 8886000
Roles of this organisation :
Review organisation

8.1 ORG-0003

Official name : European Dynamics S.A.
Registration number : 002024901000
Department : European Dynamics S.A.
Town : Athens
Postcode : 15125
Country subdivision (NUTS) : Βόρειος Τομέας Αθηνών ( EL301 )
Country : Greece
Telephone : +30 2108094500
Roles of this organisation :
TED eSender

11. Notice information

11.1 Notice information

Notice identifier/version : 4a375f8b-37fc-41a2-b455-1cee7d29c57a - 01
Form type : Direct award preannouncement
Notice type : Voluntary ex-ante transparency notice
Notice dispatch date : 21/11/2024 12:06 +00:00
Languages in which this notice is officially available : English

11.2 Publication information

Notice publication number : 00715052-2024
OJ S issue number : 228/2024
Publication date : 22/11/2024